Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Enanta Pharmaceuticals (ENTA) Other Gross PP&E Adjustments (2016 - 2025)

Enanta Pharmaceuticals' Other Gross PP&E Adjustments history spans 14 years, with the latest figure at -$37.8 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 330.29% year-over-year to -$37.8 million; the TTM value through Dec 2025 reached -$37.8 million, down 330.29%, while the annual FY2025 figure was $20.3 million, 702.26% up from the prior year.
  • Other Gross PP&E Adjustments reached -$37.8 million in Q4 2025 per ENTA's latest filing, down from $20.3 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $20.3 million in Q3 2025 to a low of -$37.8 million in Q4 2025.
  • Average Other Gross PP&E Adjustments over 5 years is -$8.4 million, with a median of -$9.1 million recorded in 2021.
  • The largest YoY upside for Other Gross PP&E Adjustments was 702.26% in 2025 against a maximum downside of 330.29% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$19.4 million in 2021, then decreased by 21.32% to -$23.5 million in 2022, then grew by 9.33% to -$21.3 million in 2023, then surged by 176.98% to $16.4 million in 2024, then crashed by 330.29% to -$37.8 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Other Gross PP&E Adjustments are -$37.8 million (Q4 2025), $20.3 million (Q3 2025), and $19.6 million (Q2 2025).